• 1. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 2. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 3. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 4. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines N-benzylpiperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Benzylpiperidines N-benzylpiperidines

Research Brief on 2-(3-(1-Benzylpiperidin-4-yl)-2-oxopropyl)-4,5-dimethoxybenzoic Acid (Donepezil Impurity, CAS: 197010-25-6)

The chemical compound 2-(3-(1-Benzylpiperidin-4-yl)-2-oxopropyl)-4,5-dimethoxybenzoic Acid, with CAS number 197010-25-6, is a known impurity of Donepezil, a widely prescribed acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease. This impurity has garnered significant attention in recent pharmaceutical research due to its potential impact on drug safety, efficacy, and regulatory compliance. Understanding the formation, characterization, and control of this impurity is crucial for ensuring the quality of Donepezil formulations.

Recent studies have focused on the analytical methods for detecting and quantifying this impurity in Donepezil formulations. Advanced techniques such as high-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) have been employed to achieve high sensitivity and specificity. These methods are essential for monitoring impurity levels during drug manufacturing and storage, ensuring compliance with stringent regulatory standards set by agencies like the FDA and EMA.

In addition to analytical advancements, research has explored the synthetic pathways leading to the formation of this impurity. Studies suggest that 2-(3-(1-Benzylpiperidin-4-yl)-2-oxopropyl)-4,5-dimethoxybenzoic Acid may arise as a byproduct during the synthesis of Donepezil or as a degradation product under certain storage conditions. Understanding these pathways is critical for developing strategies to minimize impurity formation, such as optimizing reaction conditions or implementing protective measures during storage.

Pharmacological and toxicological evaluations of this impurity have also been a focus of recent investigations. While the primary concern with impurities is their potential toxicity, preliminary studies indicate that 2-(3-(1-Benzylpiperidin-4-yl)-2-oxopropyl)-4,5-dimethoxybenzoic Acid exhibits minimal biological activity at concentrations typically found in Donepezil formulations. However, further research is needed to fully assess its safety profile, particularly in long-term exposure scenarios.

Regulatory perspectives on this impurity have evolved, with updated guidelines emphasizing the need for rigorous impurity profiling and control. The International Council for Harmonisation (ICH) guidelines, particularly ICH Q3A and Q3B, provide a framework for impurity assessment, setting thresholds for identification, qualification, and reporting. Compliance with these guidelines is essential for pharmaceutical companies to gain and maintain market approval for Donepezil products.

Future research directions include the development of more robust analytical methods, further elucidation of impurity formation mechanisms, and comprehensive toxicological studies. Collaborative efforts between academia, industry, and regulatory bodies will be key to advancing knowledge in this area and ensuring the continued safety and efficacy of Donepezil for patients with Alzheimer's disease.

• 436-77-1(Fangchinoline)
• 52-53-9(verapamil)
• 404-86-4(Capsaicin)
• 130-86-9(protopine)
• 478-61-5(Berbamine)
• 518-94-5(Cycleanine)
• 58-46-8(Tetrabenazine)
• 482-74-6(Cryptopine (~90%))
• 518-69-4(Corydaline)
• 518-34-3(Tetrandrine)